The MODULITH® SLC is the world’s first shock wave device for the treatment of refractory angina pectoris. Controlled application of precisely levelled shock wave pulses on ischemic areas of the heart muscle generates new capillaries (neo-angiogenesis) and increases circulation and metabolism. The effect is significant and lasting. Several thousand shock waves are delivered to the ischemic area under simultaneous inline-ultrasound control. ECG-triggering ensures shock wave release only during refractory period of the cardiac cycle, avoiding arrhythmic irritations. Significant reduction of complaints and enhanced cardiac function are achieved. The treatment modality does not require anaesthesia and is essentially free of side effects.